Skip to content

Tofacitinib therapy in Ulcerative Colitis patients

Evaluation of Tofacitinib efficacy for induction therapy in patients with Ulcerative Colitis

Status
Active, not recruiting
Phases
Phase 2
Study type
Interventional
Source
IRCT
Registry ID
IRCT20181217042020N1
Enrollment
50
Registered
2019-02-10
Start date
2018-12-22
Completion date
Unknown
Last updated
2019-02-25

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Ulcerative Colitis. Ulcerative colitis

Interventions

Intervention group: Medication: Tofacitinib 5 mg
Dose: 20 mg/day (4 tablets)
frequency: 2 times per day (2 tablets in the morning
two tablets in the evening)
Duration: 2 months.

Sponsors

Digestive Disease Research Institute of Tehran University of Medical Sciences
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to No maximum

Inclusion criteria

Inclusion criteria: Age> 18 years old Known case of Ulcerative Colitis Mayo score =6 in last 4 months Rectal bleeding subscore of 1 to 3 in last 4 months Endoscopic subscore of 2 or 3 in last 4 months No clinical response or clinical remission (failed treatment) after ant TNF being used for at least 12- 14 weeks or Azathioporin used for at least 8-10 weeks Unacceptable side effects after Corticostroid, Azathioprine, Mercaptopurine, Infliximab, or Adalimumab therapy

Exclusion criteria

Exclusion criteria: 1- Abnormal chest x ray pregnant women or women who plan to become pregnant, Acute infection GFR< 60 ml/ min Known case of cancer, positive TB test (PPD/ or IGRA test) Being positive for tests: HBV, HCV, HIV, CMV

Design outcomes

Primary

MeasureTime frame
Mayo score. Timepoint: At the beginning of enrollment and 2 months after start of intervention. Method of measurement: Colonoscopy.

Secondary

MeasureTime frame
Lipid profile. Timepoint: At baseline and 2 months after intervention. Method of measurement: Enzymatic method.;Liver function test. Timepoint: At baseline and 2 months after intervention. Method of measurement: Autoanalyser.;ESR. Timepoint: At baseline and 2 months after intervention. Method of measurement: Autoanalyser.

Countries

Iran (Islamic Republic of)

Contacts

Public ContactSudabeh Alatab

Digestive Diseaase Research Institute of Tehran University of Medical Sciences

sudabehalatab@yahoo.com+98 21 8241 5000

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026